EMA Authorised: Carmustine medac (previously Carmustine Obvius) (carmustine) — medac Gesellschaft für klinische Spezialpräparate mbH

View source ↗

Summary

EMA authorised Carmustine medac (carmustine) for Hodgkin lymphoma and non-Hodgkin lymphoma; the marketing authorization holder is medac Gesellschaft für klinisc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Carmustine medac (carmustine)

Snippet

Status: Authorised. Therapeutic area: Hodgkin Disease;Lymphoma, Non-Hodgkin. MAH: medac Gesellschaft für klinische Spezialpräparate mbH. Decision date: 29/08/2024